Herbomineral Medicine Peedanil Gold Exerts Analgesia in Neuropathy by Moderating Inflammatory Response and TRP...

Background: Chronic neuropathic pain, a debilitating health condition, significantly deteriorates the quality of life. Available treatment options, mostly focusing on pain management, do not target underlying cause, resulting in suboptimal and temporary outcomes. Therefore, therapeutic targeting of the cause of neuropathic pain is necessary. This study was undertaken to assess the antineuropathic potential of the herbomineral formulation, Peedanil Gold (PN-G), which has earlier been proven effective against osteoarthritis and associated inflammatory pathophysiology. Methods: Unilateral sciatic nerve chronic constriction injury (CCI) rat model was used to assess the analgesic and anti-inflammatory potential of PN-G in managing chronic neuropathy and associated pain hypersensitivities, by monitoring cold and tactile allodynia and thermal hyperalgesia. The mRNA expression levels of various pain receptors, TRPV1, TRPV4, TRPA1, and TRPM8, and inflammatory factors, p38 MAP kinase and interleukin-6 receptor (IL-6R), were evaluated through RT-qPCR. Results: Compared to untreated study animals with CCI, PN-G treatment significantly alleviated pain hypersensitivities for cold and tactile allodynia and thermal hyperalgesia to an extent comparable to that of the reference drug, gabapentin. PN-G treatment also significantly reduced the mRNA levels of pain receptors in dorsal root ganglia, implicating a strong modulation of the pain perception. Additionally, PN-G-treated animals also exhibited noticeably reduced expressions of p38 MAP kinase and IL-6R, the crucial factors in the neuropathy-associated inflammation. Conclusions: Altogether, the outcomes from the current study prove that PN-G is an effective antineuropathic agent with potential to manage pain as well as eliminate the underlying cause of neuroinflammation behind the chronicity of neuropathic pain.